Site Navigation Links

Selected Publications

Henry (A.) Glick, Ph.D.

Methods Papers / Books

Economic Evaluation in Clinical Trials

Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials, First and second editions. Oxford: Oxford University Press, 2007 and 2015.

Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, Briggs A, Sullivan SD. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015 Mar;18(2):161-72. doi: 10.1016/j.jval.2015.02.001.

Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005 Sep-Oct;8(5):521-33. doi: 10.1111/j.1524-4733.2005.00045.x.

Sampling Uncertainty

Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ. 1997 May-Jun;6(3):243-52. doi: 10.1002/(sici)1099-1050(199705)6:3<243::aid-hec269>3.0.co;2-z.

Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2001 Oct;1(1):25-36. doi: 10.1586/14737167.1.1.25.

Glick HA. Sample size and power for cost-effectiveness analysis (part 1). Pharmacoeconomics. 2011 Mar;29(3):189-98. doi: 10.2165/11585070-000000000-00000.

Glick HA. Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay. Pharmacoeconomics. 2011 Apr;29(4):287-96. doi: 10.2165/11585080-000000000-00000.

Also see chapters 7 and 8 in Glick HA, et al., Economic Evaluation in Clinical Trials

Cost and Cost Analysis

Schulman K, Burke J, Drummond M, Davies L, Carlsson P, Gruger J, Harris A, Lucioni C, Gisbert R, Llana T, Tom E, Bloom B, Willke R, Glick H. Resource costing for multinational neurologic clinical trials: methods and results. Health Econ. 1998 Nov;7(7):629-38. doi: 10.1002/(sici)1099-1050(1998110)7:7<629::aid-

Doshi JA, Glick HA, Polsky D. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health. 2006 Sep-Oct;9(5):334-40. doi: 10.1111/j.1524-4733.2006.00122.x.

Polsky D, Glick H. Costing and cost analysis in randomized controlled trials: caveat emptor. Pharmacoeconomics. 2009;27(3):179-88. doi: 10.2165/00019053-200927030-00001.

Glick HA, Polsky D. Analytic approaches for the evaluation of costs. Hepatology. 1999 Jun;29(6 Suppl):18S-22S. doi: 10.1002/hep.510290634.

Glick HA, Orzol SM, Tooley JF, Polsky D, Mauskopf JO. Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries? Health Econ. 2003 Jul;12(7):517-27. doi: 10.1002/hec.750.

Mauskopf J, Schulman K, Bell L, Glick H. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials. Pharmacoeconomics. 1996 Mar;9(3):264-77. doi: 10.2165/00019053-199609030-00007.

Also see chapters 3, 5, and 6 in Glick HA, et al., Economic Evaluation in Clinical Trials

Heterogeneity and Transferability

Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ. 1998 Sep;7(6):481-93. doi: 10.1002/(sici)1099-1050(199809)7:6<481::aid-hec353>3.0.co;2-k.

Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med. 2003 Jun 30;22(12):1955-76. doi: 10.1002/sim.1389.

Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J.Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009 Jun;12(4):409-18. doi: 10.1111/j.1524-4733.2008.00489.x. Epub 2009 Jan 12.

Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O’Brien BJ, Torti FM Jr, Tsiatis AA, Willan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J. 2005 Mar;149(3):434-43. doi: 10.1016/j.ahj.2004.11.001.

Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, Reed SD, Sculpher M, Severens JL; ISPOR Good Research Practices Economic Data Transferability Task Force. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health. 2010 Dec;13(8):1028-37. doi: 10.1111/j.1524-4733.2010.00771.x.

Also see chapter 10 in Glick HA, et al., Economic Evaluation in Clinical Trials

Research Papers

Glick HA, McElligott S, Pauly MV, Willke RJ, Bergquist H, Doshi J, Fleisher LA, Kinosian B, Perfetto E, Polsky DE, Schwartz JS. Comparative effectiveness and cost-effectiveness analyses frequently agree on value. Health Aff (Millwood). 2015 May;34(5):805-11. doi: 10.1377/hlthaff.2014.0552.

Zhang P, Hire D, Espeland MA, Knowler WC, Thomas S, Tsai AG, Glick HA; Look AHEAD Research Group. Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: Results from the Look AHEAD trial. Obesity (Silver Spring). 2016 Apr;24(4):856-64. doi: 10.1002/oby.21445. Epub 2016 Mar 8.

Espeland MA, Glick HA, Bertoni A, Brancati FL, Bray GA, Clark JM, Curtis JM, Egan C, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Hazuda HP, Hill JO, Hire D, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Killean T, Kitabchi AE, Knowler WC, Kriska A, Lewis CE, Miller M, Montez MG, Murillo A, Nathan DM, Nyenwe E, Patricio J, Peters AL, Pi-Sunyer X, Pownall H, Redmon JB, Rushing J, Ryan DH, Safford M, Tsai AG, Wadden TA, Wing RR, Yanovski SZ, Zhang P; Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes. Diabetes Care. 2014 Sep;37(9):2548-56. doi: 10.2337/dc14-0093.

Nelson RE, Lautenbach E, Chang N, Jones M, Willson T, David M, Linkin D, Glick H, Doshi JA, Stevens VW. Attributable Cost of Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Infection in a Long-term Care Center. Clin Infect Dis. 2021 Jan 29;72(Suppl 1):S27-S33. doi: 10.1093/cid/ciaa1582.

Van Pelt A, Glick HA, Yang W, Rubin D, Feldman M, Kimmel SE.Evaluation of COVID-19 Testing Strategies for Repopulating College and University Campuses: A Decision Tree Analysis. J Adolesc Health. 2021 Jan;68(1):28-34. doi: 10.1016/j.jadohealth.2020.09.038. Epub 2020 Nov 3.

Glick HA, Miyazaki T, Hirano K, Gonzalez E, Jodar L, Gessner BD, Isturiz RE, Arguedas A, Kohno S, Suaya JA.One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults. Clin Infect Dis. 2020 May 24:ciaa595. doi: 10.1093/cid/ciaa595. Online ahead of print.

Glick HA, Li P, Harvey PD. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial. Schizophr Res. 2015 Aug;166(1-3):110-4. doi: 10.1016/j.schres.2015.05.021. Epub 2015 Jun 2.

Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 May 1;114(9):798-802. doi: 10.7326/0003-4819-114-9-798

Glick H, Cook J, Kinosian B, Pitt B, Bourassa MG, Pouleur H, Gerth W. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail. 1995 Dec;1(5):371-80. doi: 10.1016/s1071-9164(05)80006-5.

Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010 Sep;105(9):1616-24. doi: 10.1111/j.1360-0443.2010.03001.x. Epub 2010 Jul 12.

Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, Vestbo J; TOwards a Revolution in COPD Health (TORCH) investigators. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2010 Mar;35(3):532-9. doi: 10.1183/09031936.00153108. Epub 2009 Aug 28.

Glick H, Willke R, Polsky D, Llana T, Alves WM, Kassell N, Schulman K. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and Australia. Int J Technol Assess Health Care. 1998 Winter;14(1):145-60. doi: 10.1017/s026646230001059x.

Glick HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther. 2002 Jan;16(1):53-9. doi: 10.1023/a:1015371616135.

Quality of Life / QALYs

Glick HA, Miyazaki T, Hirano K, Gonzalez E, Jodar L, Gessner BD, Isturiz RE, Arguedas A, Kohno S, Suaya JA. One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults. Clin Infect Dis. 2020 May 24:ciaa595. doi: 10.1093/cid/ciaa595. Online ahead of print.

Zhang P, Hire D, Espeland MA, Knowler WC, Thomas S, Tsai AG, Glick HA, Look AHEAD Research Group. Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: Results from the Look AHEAD trial. . Obesity (Silver Spring). 2016 Apr;24(4):856-64. doi: 10.1002/oby.21445. Epub 2016 Mar 8.

Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Glick HA. Preference-based quality of life in patients with Alzheimer’s disease. Alzheimers Dement. 2008 May;4(3):193-202. doi: 10.1016/j.jalz.2007.11.019. Epub 2008 May 2.

Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Low DV, Glick HA. Caregivers’ assessments of preference-based quality of life in Alzheimer’s disease. Alzheimers Dement. 2008 May;4(3):203-11. doi: 10.1016/j.jalz.2007.11.018. Epub 2008 Apr 24.

Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson’s disease. Neurology. 2002 Jul 9;59(1):103-8. doi: 10.1212/wnl.59.1.103.

Vojta C, Kinosian B, Glick H, Altshuler L, Bauer MS. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry. 2001 May-Jun;42(3):190-5. doi: 10.1053/comp.2001.23143.

Polsky D, Willke RJ, Scott K, Schulman KA, Glick HA. A comparison of scoring weights for the EuroQol derived from patients and the general public. Health Econ. 2001 Jan;10(1):27-37. doi: 10.1002/1099-1050(200101)10:1<27::aid-hec561>3.0.co;2-r.

Glick HA, Polsky D, Willke RJ, Schulman KA. A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index. Med Decis Making. 1999 Jul-Sep;19(3):265-75. doi: 10.1177/0272989X9901900305.

Willke RJ, Yen W, Parkerson GR Jr, Linet OI, Erder MH, Glick HA. Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa. Int J Impot Res. 1998 Dec;10(4):239-46. doi: 10.1038/sj.ijir.3900364.

Glick HA, Shpall EJ, LeMaistre CF, McCarron TJ, Lu ZJ, Erder MH, Glaspy JA. Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care. 1998 Summer;14(3):419-30. doi: 10.1017/s0266462300011405.

Glick HA, McCarron TJ, Althof SE, Corty EW, Willke RJ. Construction of scales for the Center for Marital and Sexual Health (CMASH) Sexual Functioning Questionnaire. J Sex Marital Ther. 1997 Summer;23(2):103-17. doi: 10.1080/00926239708405311.

Willke RJ, Glick HA, McCarron TJ, Erder MH, Althof SE, Linet OI. Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol. 1997 Jun;157(6):2124-8.

Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke. 1994 Sep;25(9):1721-5. doi: 10.1161/01.str.25.9.1721.

Also see chapter 4 in Glick HA, et al., Economic Evaluation in Clinical Trials

Cholesterol as a Risk Factor for Cardiovascular Disease

Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios.Ann Intern Med. 1994 Nov 1;121(9):641-7. doi: 10.7326/0003-4819-121-9-199411010-00002.

Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios. J Investig Med. 1995 Oct;43(5):443-50.

Criqui MH, Kinosian B, Glick H, Deedwania PC, Krauss RM. The American College of Physicians guidelines for screening blood cholesterol levels: a commentary. Am J Med. 1998 Jul 6;105(1A):75S-76S. doi: 10.1016/s0002-9343(98)00211-3.

Natarajan S, Glick H, Criqui M, Horowitz D, Lipsitz SR, Kinosian B. Cholesterol measures to identify and treat individuals at risk for coronary heart disease. Am J Prev Med. 2003 Jul;25(1):50-7. doi: 10.1016/s0749-3797(03)00092-8.

H Indices

ISI Core H Index: 46

Google H Index: 65

For a more complete listing, see:

http://www.ncbi.nlm.nih.gov/pubmed/?term=Glick+HA+OR+Glick+H

(Listing includes other indexed H and HA Glicks)